Completed PHASE3 INTERVENTIONAL 1-arm NCT00478777

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Sponsor: Celgene Corporation

Conditions Relapsed or Refractory Multiple Myeloma

Interventions Lenalidomide dexamethasone

Updated 7 times since 2017 Last updated: Sep 26, 2011 Started: Mar 31, 2007 Primary completion: Nov 30, 2007 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Relapsed or Refractory Multiple Myeloma, this trial is completed. The trial is conducted by Celgene Corporation and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation

Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bonn, Germany , Braunschweig, Germany , Burg, Germany , Chemnitz, Germany , Cologne, Germany , Dresden, Germany , Düsseldorf, Germany , Essen, Germany , Frankfurt (Oder), Germany and 29 more locations